Master protocol: The goal of this master (umbrella) clinical trial study is to learn how
novel antiretrovirals affect the HIV-1 infection in people living with HIV (PWH). The safety
and how well the study drugs are tolerated will be determined by using physical exams,
laboratory tests, and any symptoms or problems a participant might experience during the
study.
Substudy-01 (GS-US-544-5905-01) will evaluate GS-5894 in people with HIV PWH.

Study of Novel Antiretrovirals in Participants With HIV-1

San Francisco

Quest Clinical Research

GS-5894

B/F/TAF

Standard of Care

An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1

This phase II trial studies how well the combination of dabrafenib and trametinib works after
radiation therapy in children and young adults with high grade glioma who have a genetic
change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells
and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells
by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their
growth. Giving dabrafenib with trametinib after radiation therapy may work better than
treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade
glioma.

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

UCSF Medical Center-Mission Bay

Biospecimen Collection

Dabrafenib Mesylate

Lumbar Puncture

Magnetic Resonance Imaging

Radiation Therapy

Trametinib Dimethyl Sulfoxide

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

The objective of this study is to assess the long-term safety, tolerability, and efficacy of
adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who
completed participation in Study LP352-201.

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

University of California San Francisco

LP352

A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707)
in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo
controlled period, followed by a 42-week extension period.

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Investigative Site US323

Povorcitinib

Placebo

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

This phase I/Ib trial studies the side effects and best doses of capmatinib plus trametinib
when given together for the treatment of patients with MET exon 14 skipping mutation
non-small cell lung cancer that has spread to other places in the body (metastatic).
Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the
action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop
the spread of cancer cells. Trametinib is in a class of medications called kinase inhibitors.
It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
This helps stop the spread of cancer cells. Capmatinib and trametinib are "targeted
therapies." These targeted therapies work by detecting and targeting a mutation in the MET
gene. Giving Capmatinib and trametinib may kill more tumor cells in patients with metastatic
non-small cell lung cancer.

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Capmatinib

Trametinib

A Multicenter Phase I/Ib Study of Capmatinib Plus Trametinib in Patients With Metastatic MET Exon 14 Skipping Mutation Positive NSCLC

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo
plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC),
all participants will receive the docetaxel with steroid therapy and receive androgen
deprivation therapy. The intention of the study is to demonstrate that the combination of
capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall
survival of study participants, when overall survival is defined as the time from
randomization until the date of death due to any cause.

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Research Site

capivasertib

docetaxel

placebo

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and
cetuximab) works better than the usual treatment alone to shrink tumors in patients with
colorectal cancer that has spread to other places in the body (metastatic) or that cannot be
removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF.
Encorafenib is in a class of medications called kinase inhibitors. It is used in patients
whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the
action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the
spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies.
It binds to a protein called EGFR, which is found on some types of cancer cells. This may
help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib
and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor
growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal
cancer.

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Kaiser Permanente-San Francisco

Cetuximab

Encorafenib

Nivolumab

Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

CASCADE-LUNG is an event-driven, multisite, prospective, observational, blood specimen
collection study in the elevated-risk lung cancer screening population. The primary objective
is to determine the sensitivity and specificity of the Delfi Lung Cancer ScreeningTest
(DLCST).

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

San Francisco VA

Blood Sample Collection

This phase I/II trial studies how well tiragolumab and atezolizumab works when given to
children and adults with SMARCB1 or SMARCA4 deficient tumors that that has either come back
(relapsed) or does not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means
that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers
that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as
tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread.

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Atezolizumab

Computed Tomography

Fludeoxyglucose F-18

Positron Emission Tomography

Tiragolumab

X-Ray Imaging

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in
combination with standard radiation therapy in treating children and young adults with newly
diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic
change called H3 K27M mutation. It also tests whether combination of selinexor and standard
radiation therapy works to shrink tumors in this patient population. Glioma is a type of
cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when
it is growing and spreading quickly. The term, risk, refers to the chance of the cancer
coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the
brainstem that controls functions like breathing, swallowing, speaking, and eye movements).
This trial has two parts. The only difference in treatment between the two parts is that some
subjects treated in Part 1 may receive a different dose of selinexor than the subjects
treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to
determine the dose of selinexor that can be given without causing side effects that are too
severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the
Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against
HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from
growing and may kill them. It is a type of small molecule inhibitor called selective
inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells
and shrink tumors. The combination of selinexor and radiation therapy may be effective in
treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Biopsy

Selinexor

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

San Francisco, California

San Francisco

< 5 mi

Study of Novel Antiretrovirals in Participants With HIV-1

< 5 mi

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

< 5 mi

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

< 5 mi

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

< 5 mi

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

< 5 mi

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

< 5 mi

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

< 5 mi

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

< 5 mi

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

< 5 mi

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)